Gov't Relations Newsletter: Vol 14 Iss 4 - “Can We Process For This?”
Government Relations Newsletter: Vol 14, Issue 4
“Can We Process For This?”
|
By: Theodore Monroe, TFM Law “Is this legal?” Every week, merchants and payment companies call to ask whether they can process payments for peptides, hemp, adult products, vape products, and the like. The callers note that these categories are currently among their most lucrative processing opportunities.
Too often, the honest answer is “God only knows.” Let me explain why. |
![]() |
The Seven Questions
When I try to figure out whether something is okay to process, I ask a series of questions: What exactly is being sold? How is it being sold? Who is selling it? To whom? Where? When? And why is the merchant selling it, and what is the merchant saying about it?
For many products, the biggest red flag is what the merchant says about the product and why they're marketing it. The wrong claims can make even the most basic product verboten. Selling orange juice is legal, right? Yet some years ago, the FTC went after Tropicana for how it sold OJ. The FTC alleged that the company’s “Healthy Heart” advertisements falsely claimed the juice could dramatically lower blood pressure, reduce cholesterol, improve folate and homocysteine levels, and reduce the risk of heart disease or stroke.
What about selling grow lamps, which can be used to grow tomatoes, orchids, or lawful hemp, as well as marijuana? Here, the question is “why.” Intent is everything. Under federal law, selling a grow tent or a light is legal. It crosses into illegal territory only if the seller intends, or knows, that the customer will use it to violate the federal Controlled Substances Act (CSA). Heavy use of cannabis terminology or imagery in the merchant’s branding can show that intent.
Sometimes it is unclear what exactly is being sold. Are cannabis seeds capable of growing high-THC plants deemed legal hemp, or federally illegal marijuana? In other cases, “where” decides it: certain adult products and certain forms of kratom or hemp are legal to sell in West Hollywood, California, and illegal in rural Kentucky.
Peptides: A Case Study in Complexity
My favorite example of how complex all this gets involves peptides. You may want to soak your head in cold water before reading further.
Peptides are hot. They are getting a lot of attention on social media and are purported to do everything from building muscle and shedding weight to improving skin, energy, cognition, and sleep.
Peptides are short chains of amino acids, the building blocks of proteins. Think of them as smaller, simpler versions of proteins. The body strings amino acids together in countless combinations, and each combination produces unique, specific functions: orchestrating hormone activity, immune defense, tissue repair and growth, inflammation control, and digestion, among others. The body makes some peptides on its own; others come from dietary proteins such as meat, eggs, and legumes. Labs make peptides for cosmetics, medications, supplements, and injectable products.
Some peptides are the active ingredients in FDA-approved drugs for diabetes, obesity, certain endocrine disorders, and other conditions. Injectable insulin is a peptide. So are the GLP-1 drugs that treat obesity and type 2 diabetes, including semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro).
Many of the injectable peptides marketed online and by wellness clinics, however, are neither regulated nor approved by the FDA. They are experimental compounds, typically sold through “gray market” online storefronts and often labeled “for research purposes only.” Others are sold by compounding pharmacies.
So which ones are legal?
Topical cosmetic peptides
Most topical cosmetic peptides are legal and regulated by the FDA as cosmetics. They may be sold over the counter for skincare as long as they make only appearance-related claims and do not claim to treat, cure, or prevent a medical condition. Examples include:
- GHK-Cu (Copper Tripeptide-1), commonly used in anti-aging and skin-repair serums.
- Matrixyl (Palmitoyl Pentapeptide-4 / Palmitoyl Tetrapeptide-7), widely used to reduce the appearance of fine lines and support collagen.
- Argireline (Acetyl Hexapeptide-8), known for its muscle-relaxing, wrinkle-smoothing topical effects.
Even these products become illegal if they are marketed outside the bounds of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for example, by claiming to restructure deep tissue, heal internal injuries, or cure disease. The same is true if they are intended to be injected (BPC-157 and CJC-1295, for example).
Compounded GLP-1 peptides
What about GLP-1 peptides sold for weight loss? It depends on who is selling, when, what exactly is being sold, and how it is marketed.
Section 503A of the FD&C Act sets the conditions under which licensed pharmacists and physicians may compound patient-specific drugs without FDA approval. A 503A compounder may use (1) a bulk drug substance that complies with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, (2) an active pharmaceutical ingredient (API) that is a component of an FDA-approved drug, or (3) an API the FDA has placed on its 503A Bulks List through rulemaking. Although compounded drugs face fewer regulatory requirements, 503A compounders are prohibited from compounding products that are essentially copies of commercially available drugs.
That copying restriction is lifted, however, while a drug is on the FDA’s shortage list. When semaglutide and tirzepatide were in shortage (roughly 2022 through 2024), compounding pharmacies could lawfully sell GLP-1s without paying royalties or licensing fees to the patent owners, Novo Nordisk and Eli Lilly.
When the shortages ended, compounding pharmacies and their marketing companies switched tactics. They began adding vitamins such as B12 or niacinamide to the peptides and arguing that the addition created a “significant difference” tailored to the individual patient, taking the product outside the “essentially a copy” prohibition.
The FDA has sent warning letters making clear that simply adding B12, niacinamide, or another minor ingredient does not, by itself, establish a significant difference. The prescribing practitioner must document a genuine, patient-specific clinical rationale for that exact modification (a documented allergy to an inactive ingredient, for example), rather than applying it as a routine formula for mass “personalization.”
The workaround also provoked the patent owners. Eli Lilly aggressively targeted compounders through cease-and-desist letters and litigation, arguing that adding non-essential vitamins does not shield compounders from patent infringement or mass-market replication once a shortage resolves. Lilly also pressured the card brands, which responded by imposing large assessments on acquirers processing for offending merchants.
BPC-157 and the “legal enough” problem
The status of several non-GLP-1 peptides changed recently. On October 28, the FDA and the Department of Health and Human Services (HHS) shifted the compounding status of BPC-157. It has not been approved, and it has not been added to the permanent 503A Bulks List. But 503A compounding pharmacies may now compound BPC-157 without facing federal enforcement, provided they strictly meet ten specific conditions, including sourcing from FDA-registered facilities and meeting certificate-of-analysis and testing requirements.
In other words, it is still not technically compliant with the FD&C Act. This is reminiscent of the Department of Justice’s posture toward state-compliant marijuana: it is not “legal” to sell, but the feds will leave the merchant alone if it behaves itself.
The open question is what the card brands will do. Will they treat the FDA’s policy as “legal enough” to permit processing, or will they follow their current marijuana practice and bar it? Either way, I expect compounding pharmacies to be the main channel for most non-GLP-1 peptides (and possibly GLP-1s) in the immediate future.
“Research use only”
As the regulatory and processing landscape for GLP-1 peptides tightened, creative marketers pivoted to selling peptides “for research purposes.” Products sold exclusively to laboratories, universities, and scientific organizations, not to residential addresses or individual consumers, are generally legal. But the creative marketers kept the compliant labeling (vials and packaging stating “not for human or animal use”) while selling to obvious consumers.
They perform little to no KYC. They market with health, wellness, anti-aging, or muscle-building claims. Some sell syringes, bacteriostatic water, dosing instructions, or peptide calculators alongside the compounds. Each of these choices destroys the “research” exemption and makes the product an unapproved new drug under the FD&C Act.
Merchants that truly sell only to researchers are rare, but they are not unicorns. One of my clients has sold peptides for research purposes for more than forty years, exclusively to universities and laboratories. It was nonetheless caught up in the recent wave of card-brand enforcement and issued a BRAM violation despite being in compliance. (We are appealing with the brand.)
How to Process for These Merchants
So how do you safely process for merchants in these categories? Five suggestions.
- Specialize. Pick one or two categories and learn them. It is far easier to master a few areas than to become an expert in all of them.
- Get help. Several organizations publish lists of products they deem compliant (and non-compliant), and several vet and certify pharmacies and websites for compliance.
- Make the merchant do the work. Require the merchant to obtain compliance verification from trusted vendors and, when the stakes are high enough, a legal opinion from a law firm.
- Get permission. Your sponsor bank, processing partners, and the card brands need to know what you plan to do. These are not areas where you want to act first and ask forgiveness later, once the parties you depend on find out what you have been doing.
- Monitor like heck. Both underwriting and ongoing monitoring in these categories demand far more due diligence than your average card-present merchant.
And at every step, come back to the seven questions. Make sure you know and have documented them at underwriting, and keep asking them for as long as you process: what, how, who, to whom, where, when, and why.
*NOT LEGAL ADVICE: This article is for informational purposes only. It is not legal advice and should not be relied upon as such. Please check with your own internal policies and processes before taking action.

